ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Piramal invests in drug actives

by Rick Mullin
October 16, 2017 | APPEARED IN VOLUME 95, ISSUE 41

[+]Enlarge
Credit: Piramal
Piramal is investing in this facility in Riverview, Mich.
Credit: Piramal
Piramal is investing in this facility in Riverview, Mich.

Piramal Pharma Solutions will spend $55 million in the U.S. and Asia to boost contract production of active pharmaceutical ingredients. The investment will add 270,000 L of new multipurpose capacity to support a pipeline of 80 late-stage customer programs. The firm will expand its high-potency capacity in Riverview, Mich., while boosting early-stage development capabilities in Ennore, India, with kilo labs and a pilot plant. Piramal will also add early development of both drug substances and drug products in Morpeth, England, and expand R&D, automation, and IT systems at all its facilities.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment